Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-22
2005-03-22
Siew, Jeffrey (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S866000, C530S304000
Reexamination Certificate
active
06869930
ABSTRACT:
The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ε-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ε-amino group of LysB29has a lipophilic substituent; and any Zn2+complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1is present, then the insulin derivative is always present as a Zn2+complex.
REFERENCES:
patent: 3528960 (1970-09-01), Haas et al.
patent: 3823125 (1974-07-01), Grant et al.
patent: 3868356 (1975-02-01), Smyth
patent: 3868357 (1975-02-01), Smyth et al.
patent: 3869437 (1975-03-01), Shall et al.
patent: 3907763 (1975-09-01), Brandenburg et al.
patent: 3950517 (1976-04-01), Lindsay et al.
patent: 4645740 (1987-02-01), Breddam et al.
patent: 5008241 (1991-04-01), Markussen et al.
patent: 5164366 (1992-11-01), Balschmidt et al.
patent: 5208217 (1993-05-01), Panayotis
patent: 5646242 (1997-07-01), Baker et al.
patent: 5693609 (1997-12-01), Baker et al.
patent: 5905140 (1999-05-01), Hansen
patent: 5922675 (1999-07-01), Baker et al.
patent: 20010041786 (2001-11-01), Brader et al.
patent: 22 09 835 (1976-04-01), None
patent: 0 127 535 (1984-05-01), None
patent: 0 280 534 (1988-02-01), None
patent: 0 511 600 (1992-11-01), None
patent: 1 27 107 (2002-07-01), None
patent: 1343113 (1974-01-01), None
patent: 1 492 997 (1977-11-01), None
patent: 57-67548 (1982-04-01), None
patent: 1-254699 (1989-10-01), None
patent: WO 9112817 (1991-09-01), None
patent: WO 9201476 (1992-02-01), None
patent: 9507931 (1995-03-01), None
Gammeltoft, Phys. Rev. 64. 1321-1378, 1984.*
Lindsay and Shall: The Acetylation of Insulin Biochem: (1991) 121, pp. 737-745.
Brange and Langkjaer: Chemical Stability of Insulin Acta Pharm. Nord.4(3) 149-158 (1992).
MIMS Annual 1991, Section 6d “Insulin Preparations” (IMB Publishing).
MIMS Annual 1993, Section 6d “Insulin Preparations” (IMS Publishing).
Prescription Products Guide 1992, pp. 942-944, 957-958 and 1307-1308.
J. Schlicktkrull, “Insulin Crystals” (Ejnar Munksgaard) 1958, pp. 21-33.
A Marble et al., Joslin's Diabetes Mellitus, 12th Edition, 1985, pp. 380-382.
Schade: Intensive Insulin Therapy, Exerpta Medica 1983, pp. 7 and 304.
W.D. Foye: Principles of Medicinal Chemistry 1974, pp. 563-565.
Doerge: Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry 1982, pp. 774-776.
Montague: Diabets and the Endocrine Pandreas—A Biochemical Approach, 1983, pp. 36 and 37.
Samuel et al., (1978) Clin. Exp. Immunol. 33:252-260.
Lapidot et al., Journal of Lipid Research, vol. 8, pp. 142-145, (1967).
Asada et al., Pharmacetuical Research, vol. 11, No. 8, pp. 1115-1120 (1994).
Besselink et al., Applied Biochemistry and Biotechnology, vol. 43, pp. 227-246, (1993).
Boyd et al., Int. J. Peptide Protein Res. 4, pp. 109-115, (1972).
Boyd et al., Int. J. Peptide Protein Res. 4, pp. 109-114, (1972).
Bradbury et al., Eur. J. Biochem, vol. 76, pp. 573-582, (1977).
Brandenburg et al., Hoppe Seyler's Z. Physiol. Chem., vol. 353, pp. 599-616, (1972).
Cannan et al., Ann. N.Y. Acad. Sci., vol. 41, pp. 241-266, (1941).
Chan et al., Biochem. J., vol. 193, pp. 419-425, (1981).
Copper et al., Proc. Austr. Biochem Soc., vol. 3, p. 36, (1970).
Eugene Frederic. Journal of Polymer Science, vol. 12, pp. 287-300, (1954).
Friesen et al., Semisynthetic Peptides and Proteins, Offord & Dibello, pp. 161-179, (1977).
Muranishi et al., Journal of Controlled Release, vol. 19, pp. 179-188 (1992).
Brange J., Galenics of Insulin, pp. 18-100 (1987).
Blundell T. et al., The Structure In the Crystal and Its Reflection In Chemistry and Biology, vol. 26, pp. 279-402 (1972).
Markussen et al., Proc. Eng., vol. 2, pp. 157-166 (1988).
Brunfelt, ACTA Endocrinol. vol. 61, pp. 561-576 (1969).
Markussen, J. et al., Diabetologia 39: 281-288 (1996).
Krutzhals et al., J. Pharm. Sci. 85(3): 304-308 (1996).
Markussen et al., Protein Engineering 1(3):205-213 (1987).
Hashimoto et al., Pharmaceutical Research 6(2): 171-176 (1989).
Friesen, Insulin Chemistry, Structure and Function of Insulin and Related Hormones, Proceedings of the Second International Insulin Symposium Aachen, Germany, Sep. 4-7, 1979; Brandenburg and Wollmer, pp. 125-133.
Geiger et al., Hoppe Seyler's Z. Physiol. Chem. vol. 352, pp. 1487-1490, (1971).
Saul Lande, J. Org Chem., vol. 36, pp. 1267-1270, (1971).
Lande et al., Endocrinology, vol. 90, pp. 597-604, (1972).
Leclerc et al., Can, J. Chem. vol 46, pp. 1047-1051, (1968).
Lindsay et al., Eur. J. Biochem, vol. 15, pp. 547-554, (1970).
Lindsay et al., Biochem J. vol. 121, pp. 737-745, (1972).
Massey et al., Eur. J. Biochem, vol. 31, pp. 470-473, (1972).
May et al., J. Biol. Chem., vol. 253, pp. 686-690.
Saunders et al., FEBS Letters, vol. 26, pp. 286-288, (1972).
Saunders Thesis, pp. 63-67, (1974).
Saunders et al., Biochem J., vol. 165, pp. 479-486, (1977).
Schuttler, Hoppe Seyler's Z. Physiol. Chem., vol. 360, pp. 1721-1725, (1979).
Sheffer et al., Can. J. Biochem, vol. 57, pp. 489-496, (1979).
Tanford, J. Am. Chem. Soc., vol 72, pp. 441-451, (1950).
Tanford, Adv. Protein Chem., vol. 17, pp. 142-144, (1962).
Andersen Asser Sloth
Halstrom John
Havelund Svend
Jonassen Ib
Markussen Jan
Began, Esq. Marc A.
Bork, Esq. Richard W.
Green, Esq. Reza
Novo Nordisk A S
Siew Jeffrey
LandOfFree
Acylated insulin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated insulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated insulin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3440843